Ovid Therapeutics Inc. · NASDAQ:OVID
Ovid Therapeutics — Investor Presentation (November 2022)
27 slides from Ovid Therapeutics's investor presentation, November 2022
Slide 1: Ovid Therapeutics Corporate Overview
TM Ovid Therapeutics Corporate Overview (NASDAQ: OVID) ©2022 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED NOVEMBER 2022
Slide 2: Disclaimers and forward-looking statements
Disclaimers and forward-looking statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the timing and development of Ovid’s product candidate pipeline and achiev
Slide 3: Transforming the lives of individuals with epilepsies & rare neurological diseases
Transforming the lives of individuals with epilepsies & rare neurological diseases + Pipeline dedicated to addressing significant unmet + Significant financial interest in need & large addressable development/commercialization market in epilepsies & of soticlestat currently in Phase 3 neurological d
Slide 4: Team of disciplined operators & value creators
Team of disciplined operators & value creators Transformative transactions • Invested ~$75M in soticlestat for $196M upfront payment and potential milestones of $660M+ and tiered royalties Jeremy Levin Julia Tsai, Ph.D. Claude Nicaise, M.D. Jason Tardio, MBA up to 20% D. Phil, MB BChir Head, Clinica
Slide 5: Advancing epilepsy franchise & genetic seizure programs
Small molecule Advancing epilepsy franchise & genetic seizure programs Genetic target ANTICIPATED EPILEPSY PROGRAMS INDICATION/TARGET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MILESTONES OUT-LICENSED TO • Findings from two Dravet syndrome registrational studies SOTICLESTAT CH24H inhibitor • Filing marketi
Slide 6: Epilepsy is a significant & growing market
Epilepsy is a significant & growing market 3 3 U.S. WORLDWIDE… 30-40% ~65M 1 of individuals with epilepsy have seizures million Patients not controlled with antiepileptic drugs (AED) adults living with epilepsy in the US4 ~6% per year >$8B 2 Branded AED market growth 470,000 ≤17 years Market through
Slide 7: Medicines with novel mechanisms for epilepsies are needed
Medicines with novel mechanisms for epilepsies are needed Many patients continue to experience seizures despite polypharmacy Seizure-free patients (% of cohort) relative to antiseizure medication use ~30% 60 of epilepsy patients 50 remain treatment-resistant % SEIZURE FREE (OF COHORT) 40 – continuin
Slide 8: Franchise of potentially novel epilepsy medicines
Franchise of potentially novel epilepsy medicines PRECLINICAL PHASE 1 PHASE 2 PHASE 3 IN-LICENSED OV329 Programs with Potential best-in-class, oral GABA-aminotransferase inhibitor with an enhanced benefit/risk profile and administration in preclinical development for focal seizures, complementary tu
Slide 9: Soticlestat overview
Actively being studied in two Data to-date suggests potential pivotal, Phase 3 trials use in early treatment lines2 OUT-LICENSED TO TAKEDA (conducted by Takeda): • Based upon promise of seizure • Dravet syndrome (DS) control efficacy and tolerability profile OVERVIEW: observed in clinical trials • L
Slide 10: Soticlestat demonstrated statistically significant seizure reduction in Dravet syndrome
soticlestat Soticlestat demonstrated statistically significant seizure reduction in Dravet syndrome; numeric reduction in Lennox-Gastaut syndrome1 DRAVET SYNDROME DRAVET SYNDROME(CONVULSIVE SEIZURES) (CONVULSIVE SEIZURES) LENNOX-GASTAUT SYNDROME (DROP SEIZURES) Median Change from Baseline in Seizure
Slide 11: Encouraging safety & tolerability profile ELEKTRA TEAEs
soticlestat Encouraging safety & tolerability profile ELEKTRA TEAEs OVERALL ADVERSE EVENT RATES TEAEs >5% in soticlestat & 100.00% Soticlestat Placebo >3% difference from (n=71) (n=70) placebo 75.00% Pyrexia 11 (15.5%) 8 (11.4%) 50.00% n=45 25.00% Somnolence 6 (8.5%) 3 (4.3%) 0.00% TEAE Rates SAE Ra
Slide 12: Phase 3 placebo-controlled studies in DS & LGS
soticlestat Phase 3 placebo-controlled studies in DS & LGS Trials being conducted by Takeda Soticlestat BID Study 1: DS N = 142 (Add-on to SoC) Entry into OLE Placebo BID Study 2: LGS N = 234 (Add-on to SoC) Titration (4 weeks) 1 Maintenance (12 weeks) Full treatment period 16 weeks TRIAL DESIGN OUT
Slide 13: Soticlestat agreement with Takeda holds value of up to $856M
soticlestat Soticlestat agreement with Takeda holds value of up to $856M1, creating an expected non-dilutive cash stream Invested ~$26M upfront & $57M in clinical development 2021 2025* Est. 2025 and later Upfront payment Expected regulatory milestone Commercial milestones & royalties decision • All
Slide 14: A potent, next-generation GABA-aminotransferase inhibitor
A potent, next-generation GABA-aminotransferase inhibitor OVERVIEW: Increased potency has potential to deliver: OV329 • Increased seizure reduction efficacy • Improved safety profile (better ocular safety margin than A potential vigabatrin in preclinical studies) anti-seizure • Preferred dosing medi
Slide 15: OV329 is a highly potent GABA-aminotransferase inhibitor
OV329 OV329 is a highly potent GABA-aminotransferase inhibitor A potential best-in-class GABA-AT inhibitor based on a validated mechanism OPPORTUNITY: with an enhanced benefit/risk profile for treatment-resistant seizures Low GABA transmission (e.g., epilepsy) OV329 facilitates GABA transmission • E
Slide 16: Six preclinical models reaffirm OV329 seizure reduction activity
OV329 Six preclinical models reaffirm OV329 seizure reduction activity, including resistant seizure models1 Intrahippocampal Kainate Model of Maximal i.v. NMDA-Induced Mesial-Temporal 6 Hz Electrical Electroshock Pentylenetetrazol Infantile Spasm Audiogenic Amygdala Corneal Lobe Epilepsy Stimulation
Slide 17: Daily dosing significantly reduced focal seizures in MTLE model
OV329 Daily dosing (3 mg/kg) significantly reduced number of focal seizures in MTLE model 30 OV329 BASELINE 25 (3.0 mg/kg PO) (Placebo) 20 HPD Number (per period) 15 *# 10 *** ## Dose 5 # ### ### Baseline ## ** # * * 0 ** Base 0-30min Base 30- Base 60- Base 90- 10-40min 40-70min 70-100min 100-130min
Slide 18: No ocular effects seen following chronic exposure with OV329
OV329 No ocular effects seen following chronic exposure with OV329 (3 mg/kg) Vehicle OV329 3.0 mg/kg Vigabatrin 300 mg/kg Ocular effects seen in more than No ocular effects seen in 3 mg/kg OV329, q.d. half of rats treated with and vehicle groups in rats at Day 45 Vigabatrin (300 mg/kg) OVID, Data on
Slide 19: Overview: Phase 1 study
OV329 Overview: Phase 1 study • Design: Single (Part 1) and multiple (Part 2) ascending dose studies gated by cohort • Conducted at Duke University, School of Medicine • Healthy volunteers (6 active; 2 placebo) • 8 volunteers per cohort • First participant expected to be dosed before year-end 2022 •
Slide 20: OV350 & KCC2 direct activators
Innovative KCC2 activator Franchise in a program program in industry • OV350 & compound library • Consulting support by • Individual compounds potentially OVERVIEW: neuropharmacologist, suitable for: OV350 & KCC2 Prof. Steve Moss • Chemistry & lead identification • IV – acute indications direct cond
Slide 21: KCC2 transporter is central to regulating neuronal inhibition
OV350 KCC2 transporter is central to regulating neuronal inhibition, potentially reducing seizures1 Healthy Neuron Epileptic Neuron Seizures Potential Effect of OV350 OV350 seeks to directly activate the KCC2 transporter to improve chloride extrusion, thereby reversing neuronal hyperexcitability tha
Slide 22: OV350 preclinical models show rapid, stable accumulation in the brain
OV350 OV350 preclinical models show rapid, stable accumulation in the brain with a translatable pharmacodynamic biomarker1 KCC2 is expressed exclusively in neurons, OV350 rapidly accumulates in OV350 induces a shift in EEG high unlike other K/Cl co-transporters rodent brain via IV/IP dosing gamma po
Slide 23: In-vivo studies demonstrate mechanistic proof of concept
OV350 In-vivo studies demonstrate mechanistic proof of concept OV350 restores the efficacy of diazepam to terminate “refractory” Status Epilepticus in preclinical study Adult Mouse Experimental design EEG/EMG Recording Baseline Status Epilepticus Post-Status Epilepticus 1h 2h 2 – 48h Kainic acid 1.
Slide 24: Research collaboration with Gensaic
Entered early-stage research collaboration with novel, next-generation phage-derived gene delivery platform • Proprietary phage-derived platform (PDP) OVERVIEW • Based upon Nobel-prize winning science for phage display Research PDPs have potential to be: collaboration • Optimal for crossing the bloo
Slide 25: Building value through business development
Building value through business development Capital from soticlestat licensing deal, coupled with expertise and access, allows for pursuit of successive disciplined and targeted transactions Transaction Goals ` Leverage institutional Complement and enhance Ensure access to key drug delivery epilepsy
Slide 26: Investment highlights
Investment highlights + Investing in our pipeline and people today to conquer + Strong balance sheet epilepsies and brain disorders tomorrow in cash, cash $137.9M equivalents and marketable securities1 + Epilepsy franchise + Genetic seizure programs shares of common 70.4M stock outstanding2 • 2 smal
Slide 27: Conquer epilepsies & brain disorders with courageous science
Conquer epilepsies & brain disorders with courageous science ©2022 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 27
Ovid Therapeutics — Investor Presentation (November 2022) on 6ix